文献速递心境障碍

不同抑郁症定义衍生的多基因风险评分与抑郁症风险

Polygenic Risk Scores Derived From Varying Definitions of Depression and Risk of Depression.
PubMed 文献 · JAMA Psychiatry · 2021-01-01

结果显示 PRS 效应量与发现样本量成正比,样本量最大的研究 PRS 对 MDD 的 OR 为 1.75(95%CI 1.73-1.77)/SD,而基于住院记录 ICD-10 编码的 PRS OR 最低为 1.14(95%CI 1.12-1.16);在控制样本量差异后,基于符合 MDD 诊断标准患者与对照的 GWAS 所构建 PRS 是 MDD 的最佳估计指标,但对自报抑郁者不适用。

要点

  • PRS 对 MDD 的效应量与发现样本量成正比,样本量最大的研究 OR 为 1.75(95%CI 1.73-1.77)/SD。
  • 基于住院记录 ICD-10 编码的 PRS 对 MDD 的 OR 最低,为 1.14(95%CI 1.12-1.16)。
  • 控制样本量差异后,基于 MDD 诊断标准病例与对照的 PRS 是 MDD 最佳估计指标,但不适用于自报抑郁者。

核心结论

  • 增大样本量可能比加深表型定义更能提高 PRS 对抑郁症风险的估计效能。
  • 下一代 GWAS 应同时具备大样本量和广泛表型以捕获其他抑郁症定义未识别的 MDD 遗传风险因素。

研究设计与样本

  • 病例对照多基因风险评分分析,MDD 患者来自澳大利亚 Genetics of Depression 研究,对照与自报抑郁者来自 QSkin 人群队列。
  • 数据收集于 2018 年 9 月前,数据分析于 2020 年 9 月 10 日至 2021 年 1 月 27 日进行。

主要发现

  • PRS 效应量与发现样本量成正比,样本量最大的研究 PRS 对 MDD 的 OR 为 1.75(95%CI 1.73-1.77)/SD。
  • 基于住院记录 ICD-10 编码的 PRS 对 MDD 的 OR 最低,为 1.14(95%CI 1.12-1.16)。
  • 控制样本量差异后,基于 MDD 诊断标准病例与对照的 PRS 是 MDD 最佳估计指标,但对自报抑郁者不适用。
  • 该 PRS 与童年不良经历和躯体痛苦测量指标呈更高 OR 关联。

关键数值与推荐

  • 样本量最大的研究 PRS 对 MDD 的 OR 为 1.75(95%CI 1.73-1.77)/SD。
  • 基于住院记录 ICD-10 编码的 PRS 对 MDD 的 OR 为 1.14(95%CI 1.12-1.16)。

临床怎么用

  • 临床解读 PRS 对 MDD 风险估计时需考虑其发现样本量及抑郁症定义来源。
  • 基于诊断标准病例对照构建的 PRS 对 MDD 估计优于基于住院记录 ICD-10 编码或自报抑郁的 PRS。

局限性

  • 研究为病例对照设计,对照来自 QSkin 队列,可能与 MDD 病例来源人群存在差异。
  • 自报抑郁者与临床诊断 MDD 患者表型定义不同,可能影响 PRS 估计效能比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Genetic studies with broad definitions of depression may not capture genetic risk specific to major depressive disorder (MDD), raising questions about how depression should be operationalized in future genetic studies. OBJECTIVE: To use a large, well-phenotyped single study of MDD to investigate how different definitions of depression used in genetic studies are associated with estimation of MDD and phenotypes of MDD, using polygenic risk scores (PRSs). DESIGN, SETTING, AND PARTICIPANTS: In this case-control polygenic risk score analysis, patients meeting diagnostic criteria for a diagnosis of MDD were drawn from the Australian Genetics of Depression Study, a cross-sectional, population-based study of depression, and controls and patients with self-reported depression were drawn from QSkin, a population-based cohort study. Data analyzed herein were collected before September 2018, and data analysis was conducted from September 10, 2020, to January 27, 2021. MAIN OUTCOME AND MEASURES: Polygenic risk scores generated from genome-wide association studies using different definitions of depression were evaluated for estimation of MDD in and within individuals with MDD for an association with age at onset, adverse childhood experiences, comorbid psychiatric and somatic disorders, and current physical and mental health. RESULTS: Participants included 12 106 (71% female; mean age, 42.3 years; range, 18-88 years) patients meeting criteria for MDD and 12 621 (55% female; mean age, 60.9 years; range, 43-87 years) control participants with no history of psychiatric disorders. The effect size of the PRS was proportional to the discovery sample size, with the largest study having the largest effect size with the odds ratio for MDD (1.75; 95% CI, 1.73-1.77) per SD of PRS and the PRS derived from ICD-10 codes documented in hospitalization records in a population health cohort having the lowest odds ratio (1.14; 95% CI, 1.12-1.16). When accounting for differences in sample size, the PRS from a genome-wide association study of patients meeting diagnostic criteria for MDD and control participants was the best estimator of MDD, but not in those with self-reported depression, and associations with higher odds ratios with childhood adverse experiences and measures of somatic distress. CONCLUSIONS AND RELEVANCE: These findings suggest that increasing sample sizes, regardless of the depth of phenotyping, may be most informative for estimating risk of depression. The next generation of genome-wide association studies should, like the Australian Genetics of Depression Study, have both large sample sizes and extensive phenotyping to capture genetic risk factors for MDD not identified by other definitions of depression.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Mitchell BL, Thorp JG, Wu Y, et al. Polygenic Risk Scores Derived From Varying Definitions of Depression and Risk of Depression. JAMA Psychiatry. 2021. PMID: 34379077. doi:10.1001/jamapsychiatry.2021.1988

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。